MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%
Sector Heatmap
Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%
PLRX — Pliant Therapeutics, Inc. Common Stock
NasdaqPliant Therapeutics, Inc. Common Stock
$0.99
-0.04(-3.88%)
- O
- 1.03
- H
- 1.03
- L
- 0.97
- V
- 756.13K
⏱️ End-of-day dataAs of Oct 7, 2026
PLRX — Latest News & Headlines
6 StoriesDavid Raben receives a 575,000-share option at $1.05 per share from Pliant Therapeutics (PLRX). - Stock Titan
David Raben receives a 575,000-share option at $1.05 per share from Pliant Therapeutics (PLRX). Stock Titan
PLRX Oct 2026 1.000 put (PLRX261016P00001000) Stock Price, News, Quote & History - Yahoo! Finance Canada
PLRX Oct 2026 1.000 put (PLRX261016P00001000) Stock Price, News, Quote & History Yahoo! Finance Canada
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - markets.businessinsider.com
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer markets.businessinsider.com
[Form 3] PLIANT THERAPEUTICS, INC. Initial Statement of Beneficial Ownership - Stock Titan
[Form 3] PLIANT THERAPEUTICS, INC. Initial Statement of Beneficial Ownership Stock Titan
Pliant Therapeutics names David Raben as chief medical officer By Investing.com - Investing.com Canada
Pliant Therapeutics names David Raben as chief medical officer By Investing.com Investing.com Canada
PLRX’s FORTIFY Trial: Early Oncology Bet With Upside for Immune-Oncology Investors - TipRanks
PLRX’s FORTIFY Trial: Early Oncology Bet With Upside for Immune-Oncology Investors TipRanks